{
}
UBS has lowered its price target on Tandem Diabetes Care to $35 from $40 while maintaining a neutral rating. The company specializes in advanced insulin delivery systems, including the Tandem Mobi and t:slim X2 insulin pumps, both featuring Control-IQ technology for automated insulin delivery. These pumps are compatible with various infusion sets and can be updated via software, enhancing user experience and glycemic control.
Tandem Diabetes Care Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers price target for tandem diabetes care to thirty five dollars
14:41 27.02.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Finance Mergers & Acquisitions
Market Analysis and Predictions
CEO Changes
Banking Regulations
Financial Scams and Security
Global Financial Events
Industry Mergers & Acquisitions
Retail and Consumer Goods
Hedge Funds & Private Equity
Real Estate Investments
Startups & Entrepreneurship
Domestic Politics
Government Policies
Workplace Trends
Supply Chain Management
Political Scandals
Cryptocurrency Trends
Countries:
Companies:
Berkshire Hathaway Inc.
Barclays plc
UBS Group AG
Google Inc.
Raiffeisen Bank International AG
Robert W. Baird & Co. Inc.
Charles Schwab Investment Management Inc.
Jefferies Financial Group Inc.
Raymond James Financial Inc.
EFG International AG
ASML
Liechtensteinische Landesbank AG
UBS Group SA
DEUTSCHE BANK AG
The Goldman Sachs Group, Inc.
Berner Kantonalbank
Fifa
Carvana CO.
Warner Bros. Discovery Inc.
Huntington Ingalls Industries Inc.
Currencies:
United States Dollar
Swiss Franc
Euro
Chinese Yuan
British Pound Sterling
Indian Rupee
United Arab Emirates Dirham
Hong Kong Dollar
Australian Dollar
Japanese Yen
Omani Rial
South African Rand
Russian Ruble
Egyptian Pound
Malaysian Ringgit
People: